

Adaptimmune Therapeutics plc

Results of Annual General Meeting

15 July 2026

Adaptimmune Therapeutics plc (the "Company") announces that at its Annual General Meeting held on 29 June 2026, each of the resolutions set out in the Notice of Annual General Meeting was voted on by poll. Resolutions 1 to 6 were duly passed and resolution 7 did not pass.

Resolution	Type	Result
1. To re-appoint Chris Hill as a director	Ordinary	Passed
2. To re-appoint Garry Menzel as a director	Ordinary	Passed
3. To re-appoint Grant Thornton LLP as auditors	Ordinary	Passed
4. To authorise the directors to determine the auditor's remuneration	Ordinary	Passed
5. To receive and adopt the 2025 annual accounts and reports	Ordinary	Passed
6. To authorise the directors to allot shares	Ordinary	Passed
7. To disapply pre-emption rights	Special	Not passed

A copy of the resolution number 6, passed at the meeting has been filed with the Registrar of Companies.

Chris Hill
Company Secretary